ADXN logo

ADDEX THERAPEUTICS LTD

ADXNNASDAQ
🏆 #5090 by market capUS Equity
$2.85▼ $0.48 (−14.31%)
Market closed · at close
🔔
Track ADXN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 14.3%
7d▲ 0.0%
14d▲ 0.0%
30d▼ 14.3%
ytd▼ 64.4%
1y▼ 70.5%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
-92.6%
Declining
📊Gross Margin
41.2%
Healthy
💵FCF Margin
-3780.1%
Thin
⚖️P/S Ratio
42.3x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.85 – $2.85
52-Week Range
$2.56 – $10.43
Volume (shares)
100
Avg Volume (shares)
—
Shares Outstanding
1.2M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$29,972
Last Q Revenue
$9,908
P/E Ratio
-0.4
P/S Ratio
42.3x
EPS (TTM)
$-4.73
Dividend Yield
0.00%
Dilution (1yr)
+45.5%
ADXN logo

ADDEX THERAPEUTICS LTD

ADXN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$30K▼ −92.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▲ +2.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$2M▼ −61.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.2M▲ +45.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$2M YoY
StockOtter · stockotter.space

About ADDEX THERAPEUTICS LTD

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
9 analysts
Strong Buy0
Buy0
Hold2
Sell5
Strong Sell2
Ratings as of Jan 2026

Latest News & Updates

News unavailable.